Although, SMAD4 was not genetically co-occurred with TP53 and CDKN2A, the expression levels of SMAD4 were also relatively higher in pancreatic cancer patients with KRAS mutation, TP53 mutation or CDKN2A deletion (Figure 3E). This evidence concerns the gene TP53 and pancreatic neoplasm.